🔥Telegram İfşa

What is PSMA, and why does it matter? An over expression of PSMA has been linked to #prostatecancer and worse outcomes for patients. Staying proactive is key to managing disease. No matter how small your concern is each question matters. #Movember novartis.social/601294aao

More than 2 million people are diagnosed with #LungCancer yearly, and each one has their own unique cancer journey. At Novartis, we are committed to improve patient outcomes through innovative medicines. Learn more this #LCAM: go.novartis.social/3MrqjNx

We are dedicated to pushing the boundaries of #CancerCare to support patients worldwide. This #NETCancerDay, learn more about this often misdiagnosed cancer type due to the vague nature of its common symptoms that can be interpreted as other conditions. go.novartis.social/45W9T6Z

Despite accounting for more than 2 million new diagnoses each year, more needs to be down to tackle the barriers to better care and patient outcomes for those living with #LungCancer. We are committed to pushing boundaries and focusing on more understanding around the condition.

With many #radioligandtherapies (RLTs) in our pipeline & clinical trials underway, we’re expanding our ability to deliver to patients today & into the future. From production to administration, we’re working to change the way patients receive their care. go.novartis.social/40BoGmy

Our leadership in #radioligandtherapy (RLT) is powered by our people, many of whom have deep personal connections to cancer and understand how RLT can potentially impact the lives of those touched by cancer. go.novartis.social/3QVgOZT

Metastatic #prostatecancer is when the cancer spreads to other parts of the body. Approximately 700,000 men are currently living with this metastatic disease. At Novartis, we are making the promise of next-generation medicines a reality for people living with cancer. #Movember

#Movember: Your PSMA levels can determine the health of your prostate and if you need to seek additional care. Stay proactive – consult your doctor and schedule regular check-ups to stay on top of your prostate health. novartis.social/60119hBNS

At #SABCS23 & #ASH23, we are presenting data from over 100 trials across its breast cancer and hematology portfolios, including significant data updates in breast cancer, PNH and CML. #NovartisNews go.novartis.social/3sFM1qs

Patients at risk of recurrence from #earlybreastcancer need more options to stay cancer-free. The updated analysis from our Phase III NATALEE trial in a broad population with HR+/HER2- #EBC at #SABCS23 could help transform adjuvant care. Learn more: go.novartis.social/3RyHuQk

Novartis expands production with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis. go.novartis.social/4aIdVU2 #NovartisNews

Today, Indiana state officials, and professional and patient groups joined us for an opening ceremony event to celebrate our new #radioligandtherapy manufacturing facility in Indianapolis. RLT is changing the way cancer is treated, and Novartis is proud to lead the way.

Together with scientists and patients, we are striving to address unmet needs for adults with newly diagnosed #CML, unlock new possibilities for cancer patients, and deliver more equitable care. Let’s #ReimagineMedicine together. #ASCO24 #EHA24

1.2 to 1.5 million people are living with chronic myeloid leukemia (#CML) worldwide. This new data presented at #ASCO24 could offer hope to adults living with this difficult disease, advancing our mission to #reimaginemedicine for these patients.

x.com/NovartisUS/sta…

Together with the patients, doctors and researchers who collaborated to enable today’s FDA approval of a new medicine to help prevent recurrence after early #breastcancer, we’re #reimaginingmedicine for people whose experience with this disease doesn’t end with remission. #bcsm

Chronic myeloid leukemia (#CML) is a chronic disease that requires long-term daily therapy. Today’s FDA approval adds another choice for people living with CML. #ReimaginingMedicine

This FDA approval for adults with newly diagnosed chronic myeloid leukemia (#CML) is momentous for the clinical and patient communities. As the latest milestone in our 20+-year legacy in CML innovation, we are excited to bring new treatment options to patients who need them.

Join us at #SABCS24 to explore the stories of people touched by #breastcancer, as shared in their own words. Our Novartis exhibit, located near product theater B, aims to amplify the community’s voices to inspire attendees, as we reimagine medicine together. #bcsm

This FDA approval provides health care teams with more options to address the individual needs of patients living with advanced cancers earlier in the treatment journey. #ReimaginingMedicine